AADI News and Press, Aadi Bioscience Inc. From 11/07/23

2023-11-07 15:14:43 ET More on Aadi Bioscience Seeking Alpha’s Quant Rating on Aadi Bioscience Historical earnings data for Aadi Bioscience Financial information for Aadi Bioscience For further details see: Aadi Bioscience Q3 2023 Earnings Preview

Aadi Bioscience to Participate in Jefferies London Healthcare Conference PR Newswire LOS ANGELES , Nov. 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision ...

Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update PR Newswire Company to Host Conference Call and Webcast on Wednesday, November 8, 2023 LOS ANGELES , Nov. 1, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a comme...

Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting PR Newswire Aadi initiates Phase 2 trial investigating the combination of nab-sirolimus with letrozole for the treatment o...

Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium PR Newswire LOS ANGELES , Oct. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmace...

Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) PR Newswire LOS ANGELES , Oct. 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commerciali...

2023-10-02 08:16:39 ET Aadi Bioscience ( NASDAQ: AADI ) appoints Dave Lennon, Ph.D. as President, board member and Chief Executive Officer. In connection with Dr. Lennon's appointment, Scott Giacobello, who served as Interim Chief Executive Officer and President since Mar...

Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer PR Newswire Dr. Lennon brings over 20 years of pharmaceutical experience, including deep expertise in the development and commercialization of mTOR inhibitors Leadership transition exp...

Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PR Newswire LOS ANGELES , Sept. 20, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company ...

Aadi Bioscience to Participate at Upcoming Investor Conferences PR Newswire LOS ANGELES , Sept. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically...